| Document |
Document Title |
|
WO/2023/112000A2 |
The present invention provides the method for the separation of at least more than two Low molecular weight (LMWs) impurities present in the protein mixture comprising fusion protein CTL4-IgG1 by using Capillary Electrophoresis-Sodium do...
|
|
WO/2023/109835A1 |
Provided in the present invention are a VEGF-CRM197 recombinant fusion protein vaccine, and a preparation method therefor and the use thereof. Specifically, provided in the present invention is that truncated VEGF, namely a VEGF1-107 ant...
|
|
WO/2023/105074A1 |
The present invention relates to a photochemical process for the manufacturing of a C-terminal α-amide, which are a class of compounds that represent up to half of all biologically relevant peptide hormones. The invention provides mild,...
|
|
WO/2023/106356A1 |
The present invention addresses the problem of providing a method for producing a peptide compound at a high yield, a reagent for forming a protective group at a high yield, and a novel substituted benzyl compound. The present invention ...
|
|
WO/2023/107830A1 |
Amyloid oligomer compositions and amyloid monomer compositions used to make amyloid oligomer compositions are provided. Also provided are reagents and kits thereof that find use in preparing these compositions. These amyloid oligomer com...
|
|
WO/2023/104874A2 |
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may...
|
|
WO/2023/106291A1 |
The present invention employs a method for producing protein crystals, said method including a step for incubating a crystallization solution containing a cell-free protein synthesis system, a crystallization control agent, and a nucleic...
|
|
WO/2023/103005A1 |
Provided are a method for enriching an antibody by using an affinity chromatography medium and the use thereof. The method comprises: (1) cross-linking an antigen and GST by mean of glutaraldehyde to form an antigen-GST complex; (2) conn...
|
|
WO/2023/103744A1 |
A method for extracting growth factors from platelets, comprising: centrifuging a blood sample of a preset volume to obtain platelet-rich plasma; removing iron ions in the platelet-rich plasma by using a magnetic base method; performing ...
|
|
WO/2023/105497A1 |
The present invention provides a method of preparation of GLP-1 peptides by using different peptide fragments having amino acid sequences SEQ ID NO:1 (Fragment IG), SEQ ID NO:2 (Fragment SG), Fragment BG, SEQ ID NO:3, and SEQ ID NO:4 5 a...
|
|
WO/2023/100795A1 |
By using a polymer compound represented by formula IV and a production method thereof, provided is a novel protein aggregation inhibitor that exhibits a protein aggregation inhibitory effect when added at a low concentration and, after o...
|
|
WO/2023/097475A1 |
A method for constructing an eukaryotic expression vector of a human PAK1 protein, comprising the steps of: 1) carrying out PCR amplification to obtain a PAK1 gene fragment; 2) linking to an eukaryotic expression vector to obtain a recom...
|
|
WO/2023/098007A1 |
An intelligent conversion double-stimuli-responsive probe chelated with metal ions, and a preparation method therefor and the use thereof. The probe can be self-assembled into large nanoparticles in a water buffer solution, and the large...
|
|
WO/2023/101490A1 |
According to the manufacturing method of the present invention, Ganirelix can be obtained in high purity and high yield, and the commercial mass-production process therefor is feasible, and also, an economical advantage, that is, the red...
|
|
WO/2023/102255A1 |
Disclosed are conjugates and methods of identifying ligands for substrates using said conjugates. Also disclosed herein are methods of making the conjugates.
|
|
WO/2023/098920A1 |
A dual-targeting compound, and a preparation method therefor and the use thereof, which relate to the fields of nuclear medicine and molecular imaging. A radionuclide-labeled dual-targeting compound, having a structure as shown in formul...
|
|
WO/2023/099382A1 |
The invention relates to a method for producing at least one fibroin solution, having the following method steps performed in the order specified: - providing fibroin; - dissolving the fibroin in a first solvent system to produce a fibro...
|
|
WO/2023/098523A1 |
The present invention relates to recombinant collagen, a preparation method therefor and an application thereof, and in particular, to a recombinantly expressed full-length collagen α1 chain, a preparation method therefor and an applica...
|
|
WO/2023/099876A1 |
The present invention relates to an affinity purification system comprising a polypeptide (protein) that binds selectively (e.g. specifically) and reversibly to its cognate peptide tag (ligand). In particular, the polypeptide comprises: ...
|
|
WO/2023/093708A1 |
The present invention relates to the field of medicine synthesis. Disclosed is an anti-syncytial virus (RSV) membrane fusion inhibitor. The anti-syncytial virus membrane fusion inhibitor of the present invention is used for preparing a p...
|
|
WO/2023/094833A1 |
The present invention relates to compounds of Formula (I) that target PMS2, a component of DNA Mismatch Repair (MMR) wherein R2, R4, R6, A1, A2, A4, L and Q are each as defined herein. The present invention also relates to processes for ...
|
|
WO/2023/093164A1 |
Provided are a polypeptide-metal cluster probe for specifically recognizing a circulating tumor cell (CTC) membrane protein, and the application thereof in quantitative measurement, which belong to the technical field of medical testing....
|
|
WO/2023/095665A1 |
This antibody isolation method comprises: a step for adding a solution containing antibodies to a column filled with an antibody adsorption material containing an insoluble porous carrier and an Fc-binding protein immobilized on the carr...
|
|
WO/2023/093303A1 |
Disclosed in the present invention are a P53-targeted polypeptide and a use thereof in preparation of a drug for treating cancer. The polypeptide specifically binds to a P53 mutant, and the polypeptide is selected from any one or more of...
|
|
WO/2023/088464A1 |
The present invention relates to the field of biomedicine, and particularly relates to a CD300LD inhibitor and a use thereof in preparation of a tumor immunotherapy product. According to the present invention, the CD300LD inhibitor adjus...
|
|
WO/2023/087482A1 |
Provided are a leucine aminopeptidase and glutathione dual-stimulation response type probe, a preparation method therefor, and an application thereof. The probe Ce6-Leu is subjected to a click condensation reaction under the stimulation ...
|
|
WO/2023/089594A1 |
The present invention relates to tirzepatide or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof. The present inven...
|
|
WO/2023/087555A1 |
Provided in the present application are a novel coronavirus recombinant protein CRM-RBD and a preparation method therefor. The recombinant protein can induce the body to produce a broad-spectrum neutralizing antibody.
|
|
WO/2023/087052A1 |
Disclosed herein is a process for producing a lactoferrin powder. The process comprises extracting lactoferrin from a native lactoferrin-containing substance and concentrating the extracted lactoferrin to produce a liquid concentrate in ...
|
|
WO/2023/092133A1 |
Provided are in vivo engineered proteins. The engineered protein may be covalently bound to a ligand.
|
|
WO/2023/087871A1 |
The present invention belongs to the field of nuclear medicine, and relates to a granzyme B targeting complex, a radiopharmaceutical, a preparation method therefor, and a use thereof. The structure of the granzyme B targeting complex is ...
|
|
WO/2023/088073A1 |
The present invention relates to a multifunctional American ginseng hydrolyzed peptide, a preparation method therefor, and an application thereof. The content of active peptide in the American ginseng hydrolyzed peptide provided by the p...
|
|
WO/2023/087491A1 |
A preparation method for a DNA origami-based tumor neoantigen delivery system, comprising: selecting eight single-stranded DNAs, wherein 20 nt ployT structures extend from the 5' ends of three of the single-stranded DNAs and are used for...
|
|
WO/2023/085342A1 |
The present invention provides: a modified form of a SapB protein; a method for preparing a SapB protein and a modified form thereof; and an aqueous solution in which a SapB protein or a modified form thereof is dissolved.
|
|
WO/2023/082803A1 |
The present invention relates to an active polypeptide for inhibiting the growth of liver cancer cells, and a preparation method therefor and the use thereof. The amino acid sequence of the active polypeptide is VNNSSLIGLGYTQTLKPGIK. The...
|
|
WO/2023/086960A1 |
Provided herein are methods, reagents, and kits for the isolation of sperm cells from other cell types and the purification of sperm-associated DNA from a complex sample. In particular, methods, reagents, and kits are provided for the se...
|
|
WO/2023/084967A1 |
The present invention provides a production method of γ-glutamylcysteine (γ-EC) that is applicable to industrial production, and immobilized NsPCS enzyme (immobilized NsPCS) to be used in the production method. This production method, ...
|
|
WO/2023/077685A1 |
Disclosed in the present application is a liquid preparation of a monoclonal antibody against human interleukin-33, which liquid preparation comprises a monoclonal antibody against human interleukin-33 with a protein concentration of 120...
|
|
WO/2023/080164A1 |
The present invention provides a β-ketoester of a protein that contains an amino acid having a hydroxyl group, wherein the hydroxyl group forms an ester bond together with a group represented by formula (1) (wherein R represents a C1-6 ...
|
|
WO/2023/077413A1 |
Provided are a protein containing an amino acid sequence capable of binding to a peptide fragment of a substrate GPRP, a fibrinogen-like protein 1 (FGL1) containing the amino acid sequence, and a fibrinogen domain (FD) of the FGL1, where...
|
|
WO/2023/079310A1 |
The invention provided herein relates to methods for protein synthesis, characterisation and purification on a digital microfluidic device.
|
|
WO/2023/075812A1 |
Systems and methods are described in which proteins are isolated from complex solution using successive chromatographic separations that retain the protein of interest in the flow-through. At least one of the chromatography media used is...
|
|
WO/2023/072145A1 |
A method for purifying single-stranded DNA is provided. The method can comprise: mixing a sample containing single-stranded DNA with a single-stranded DNA binding protein, and incubating for a first time period to obtain a first product,...
|
|
WO/2023/070948A1 |
The present application discloses a liquid preparation of an anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody, comprising the anti-human thymic stromal lymphopoietin (TSLP) monoclonal antibody and an amino acid protecti...
|
|
WO/2023/074642A1 |
[Problem] To provide a immunoglobulin-binding protein which has improved chemical stability, particularly stability with respect to alkalis, an immunoglobulin-binding protein which enables antibody elution in mild pH conditions, and an a...
|
|
WO/2023/074991A1 |
The present invention relates to a method for production of a bioactive substance using blood, and application of the product obtained by the method, the method comprising the steps of: a) collecting animal blood treated with 0.32% triso...
|
|
WO/2023/069437A1 |
Settling or settler devices for separating particles from a bulk fluid with applications in numerous fields. The devices include inclined sliders with an arcuate cross-section arranged in a space within a housing. These devices are usefu...
|
|
WO/2023/068296A1 |
The present invention relates to a method for producing compounds that have at least one structure represented by formula (I) or (II), wherein the production method comprises a step for contacting a compound having at least one structure...
|
|
WO/2023/068740A1 |
The present invention relates to: a method for purifying a fusion protein having an IgG Fc domain, comprising performing a multimodal chromatographic purification step on a raw material containing a fusion protein having an IgG Fc domain...
|
|
WO/2023/068999A1 |
A device (100, 100´, 100´´) for separating an analyte (200) from other components in an electrolytic solution. The device comprises a housing (114, 115, 116, 117, 118, 119) provided with a solution inlet (104) and a solution outlet (1...
|
